In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Immune Response initiates phase I trial of brain tumour vaccine
Schering-Plough in licensing agreement with Three Rivers
Schering-Plough and Merck Provide Update on Distribution Agreement
Schering-Plough and Merck Provide Update on Distribution Agreement
Schering-Plough gains allergic rhinitis approval
DTI-015 has been granted Orphan Drug Designation
Schering-Plough Completes Acquisition of Organon BioSciences
Schering-Plough Completes Acquisition of Organon BioSciences